This prospective, pragmatic clinical trial provides real-world evidence of increased glycemic control and patient treatment satisfaction in adults with T2DM initiating treatment with the V-Go insulin delivery device, compared with patients using standard delivery of insulin and treatment optimization. The gene discussed is INS; the disease is type 2 diabetes mellitus.